Glutamate carboxypeptidase II (GCPII)
Glutamate carboxypeptidase II (GCPII), also known as prostate-specific membrane antigen (PSMA), is a type II transmembrane glycoprotein that plays a crucial role in the metabolism of glutamate and is highly expressed in prostate cancer tissues.
Glutamate carboxypeptidase II (GCPII), also known as prostate-specific membrane antigen (PSMA), is a type II transmembrane glycoprotein that plays a crucial role in the metabolism of glutamate and is highly expressed in prostate cancer tissues. It functions as a carboxypeptidase, hydrolyzing the C-terminal glutamate residues from peptides and proteins, which is significant in various physiological processes, including neurotransmission and tumor progression. Due to its overexpression in prostate cancer, GCPII has emerged as a prominent target for diagnostic imaging and therapeutic strategies, particularly in the context of metastatic castration-resistant prostate cancer (mCRPC).
Where the papers sit
14 papers from the last 6 months study Glutamate carboxypeptidase II (GCPII) directly · updated from PubMed 16 Nov 2026
Study type 2 clinical trials · 3 human data · 8 preclinical · 1 unclassified
Themes one subject · 1 paradigm shift
Those 14 are all about one subject.
-
PSMA-Targeted Prostate Cancer Theranostics
PSMA targeting is expanding from PET diagnosis into integrated radionuclide therapy and drug delivery for prostate cancer. [177Lu]Lu-PSMA-617 and [225Ac]- or [161Tb]-based agents extend treatment across beta- and alpha-emitting platforms, with early evidence of efficacy and anticancer immunity. Albumin binding, bivalent ligands, nanoparticles, dendrimers and acoustic enhancement are being used to improve pharmacokinetics, tumor accumulation and payload delivery. Imaging studies continue to address PSMA flare, metastatic mimics and equivocal lesions, while CAR-T and combination approaches remain emerging directions.
PSMA/GCPII expression is not sufficiently prostate-cancer-specific or uniform to serve as a standalone disease or target-readout marker
The glioblastoma multiforme mouse model studied with acoustic cluster therapy and [^68Ga]Ga-PSMA-617, and the review of PSMA-PET/CT metastasis mimics, both depart from the assumption that PSMA identifies prostate-cancer tissue selectively and consistently. In the glioblastoma model, PSMA was explored as a target despite low and variable expression, while the metastasis-mimics analysis found PSMA uptake in physiologic tissues and diverse benign and malignant conditions that can resemble prostate-cancer metastases. Together, these findings mean that PSMA/GCPII signal cannot be treated as intrinsically specific for prostate-cancer metastasis or as evidence of uniform target availability; interpretation and targeting must account for expression heterogeneity, lesion anatomy, and clinical context. 42308923Jun 42391030Jul
Papers
The 14 papers from the last 6 months that study Glutamate carboxypeptidase II (GCPII) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
PSMA-Targeted Prostate Cancer Theranostics (14)
- Sugar Amino Acid Linkers for the Design of [18F]SiFA-PSMA Radioligands. ChemMedChem · 13 Aug 2026 PMID 42587267
- Real-World Outcomes of [177Lu]Lu-PSMA-617 in the French Early-Access Program for Patients with Metastatic Castration-Resistant Prostate Cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 6 Aug 2026 PMID 42562607
- Prostate specific membrane antigen targeted ultrasmall manganese ferrite nanoparticles for PET/MR imaging of prostate cancer. Journal of materials chemistry. B · 30 Jul 2026 PMID 42529845
- Improving Pharmacokinetics of PSMA/GRPR-Targeting Radiolabeled Heterodimer through Enhanced Albumin Binding. Molecular pharmaceutics · 14 Jul 2026 PMID 42447187
- Alpha-Particle Therapy with an Actinium-225 Labeled Bivalent Inhibitor of Prostate-Specific Membrane Antigen is Therapeutically Efficacious in a Mouse Model of Prostate Cancer. Journal of medicinal chemistry · 4 Jul 2026 PMID 42400871
- Dual-Targeted Radionuclide Therapy with 161Tb Instigates Anticancer Immunity in "Cold" Murine Prostate Tumor. Molecular pharmaceutics · 3 Jul 2026 PMID 42397707
- Comprehensive Approach to Prostate Cancer Metastasis Mimics at Prostate-Specific Membrane Antigen PET/CT. Radiographics : a review publication of the Radiological Society of North America, Inc · 2 Jul 2026 PMID 42391030
- PSMA-Targeted Dendrimer Delivery of Sorafenib Enhances MAPK Suppression and Anti-Angiogenic Activity in Prostate Cancer. Journal of medicinal chemistry · 24 Jun 2026 PMID 42342430
- Systematic Investigation of Fatty Acids with Different Carbon-Chain Length as Albumin Binder to Improve Tumor Accumulation of Radioligands. Bioconjugate chemistry · 23 Jun 2026 PMID 42332998
- The DARO-flare trial: evaluating the impact of darolutamide on prostate-specific membrane antigen (PSMA) flare and its implications for imaging and staging of hormone-sensitive prostate cancer - study protocol. BMJ open · 18 Jun 2026 PMID 42315278
- Acoustic cluster therapy mediated enhancement of [68Ga]Ga-PSMA-617 in a murine glioblastoma multiforme model verified by simultaneous PET/MRI. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 17 Jun 2026 PMID 42308923
- Piggybacking toward Progress for CAR T-Cell Therapy in Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 17 Jun 2026 PMID 42307267
- Triphosgene-free solid-phase synthesis of urea-containing PSMA-targeting peptides for radiotheranostics: a comparative study. Organic & biomolecular chemistry · 16 Jun 2026 PMID 42300211
- Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial. The Lancet. Oncology · 10 Jun 2026 PMID 42269655
By study type
Clinical trials (2)
- The DARO-flare trial: evaluating the impact of darolutamide on prostate-specific membrane antigen (PSMA) flare and its implications for imaging and staging of hormone-sensitive prostate cancer - study protocol. BMJ open · 18 Jun 2026 PMID 42315278
- Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial. The Lancet. Oncology · 10 Jun 2026 PMID 42269655
Human data, design not indexed (3)
- Comprehensive Approach to Prostate Cancer Metastasis Mimics at Prostate-Specific Membrane Antigen PET/CT. Radiographics : a review publication of the Radiological Society of North America, Inc · 2 Jul 2026 PMID 42391030
- Piggybacking toward Progress for CAR T-Cell Therapy in Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 17 Jun 2026 PMID 42307267
- Triphosgene-free solid-phase synthesis of urea-containing PSMA-targeting peptides for radiotheranostics: a comparative study. Organic & biomolecular chemistry · 16 Jun 2026 PMID 42300211
Preclinical: animal, cell and lab studies (8)
- Sugar Amino Acid Linkers for the Design of [18F]SiFA-PSMA Radioligands. ChemMedChem · 13 Aug 2026 PMID 42587267
- Prostate specific membrane antigen targeted ultrasmall manganese ferrite nanoparticles for PET/MR imaging of prostate cancer. Journal of materials chemistry. B · 30 Jul 2026 PMID 42529845
- Improving Pharmacokinetics of PSMA/GRPR-Targeting Radiolabeled Heterodimer through Enhanced Albumin Binding. Molecular pharmaceutics · 14 Jul 2026 PMID 42447187
- Alpha-Particle Therapy with an Actinium-225 Labeled Bivalent Inhibitor of Prostate-Specific Membrane Antigen is Therapeutically Efficacious in a Mouse Model of Prostate Cancer. Journal of medicinal chemistry · 4 Jul 2026 PMID 42400871
- Dual-Targeted Radionuclide Therapy with 161Tb Instigates Anticancer Immunity in "Cold" Murine Prostate Tumor. Molecular pharmaceutics · 3 Jul 2026 PMID 42397707
- PSMA-Targeted Dendrimer Delivery of Sorafenib Enhances MAPK Suppression and Anti-Angiogenic Activity in Prostate Cancer. Journal of medicinal chemistry · 24 Jun 2026 PMID 42342430
- Systematic Investigation of Fatty Acids with Different Carbon-Chain Length as Albumin Binder to Improve Tumor Accumulation of Radioligands. Bioconjugate chemistry · 23 Jun 2026 PMID 42332998
- Acoustic cluster therapy mediated enhancement of [68Ga]Ga-PSMA-617 in a murine glioblastoma multiforme model verified by simultaneous PET/MRI. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 17 Jun 2026 PMID 42308923
Unclassified: not yet indexed with MeSH (1)
- Real-World Outcomes of [177Lu]Lu-PSMA-617 in the French Early-Access Program for Patients with Metastatic Castration-Resistant Prostate Cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 6 Aug 2026 PMID 42562607
Written from 14 PubMed abstracts, each one listed by PMID above. Published: 2026-06-17. Last written: 2026-08-26 by GPT. Drafted by language models from published abstracts; not medical advice.